# BioNexus Gene Lab Corp: financial statements, quarterly

BGLC · Nasdaq · CIK 1737523 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/bglc.md) · [Financials](/companies/bglc/financials.md) · [Filings](/companies/bglc/filings.md) · [Insiders](/companies/bglc/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/bglc/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $k | [2,554](/filings/0001477932-24-007332.md) | [2,273 d](/filings/0001477932-25-002725.md) | [2,382](/filings/0001477932-25-003821.md) | [1,975](/filings/0001477932-25-006023.md) | [2,630](/filings/0001477932-25-008343.md) | [2,524 d](/filings/0001477932-26-002218.md) | [2,137](/filings/0001477932-26-003242.md) | [2,260](/filings/0001477932-26-005093.md) | [2,544](/filings/0001477932-25-008343.md) | [484 d](/filings/0001477932-26-002218.md) | [22.8](/filings/0001477932-26-003242.md) | [76.2](/filings/0001477932-26-005093.md) |
| Cost of revenue | $k | [2,199](/filings/0001477932-24-007332.md) | [2,007 d](/filings/0001477932-25-002725.md) | [2,017](/filings/0001477932-25-003821.md) | [1,686](/filings/0001477932-25-006023.md) | [2,304](/filings/0001477932-25-008343.md) | [2,215 d](/filings/0001477932-26-002218.md) | [1,794](/filings/0001477932-26-003242.md) | [1,892](/filings/0001477932-26-005093.md) | [2,166](/filings/0001477932-25-008343.md) | [488 d](/filings/0001477932-26-002218.md) | [23.6](/filings/0001477932-26-003242.md) | [63.2](/filings/0001477932-26-005093.md) |
| Gross profit | $k | [354](/filings/0001477932-24-007332.md) | [267 d](/filings/0001477932-25-002725.md) | [365](/filings/0001477932-25-003821.md) | [289](/filings/0001477932-25-006023.md) | [327](/filings/0001477932-25-008343.md) | [309 d](/filings/0001477932-26-002218.md) | [343](/filings/0001477932-26-003242.md) | [368](/filings/0001477932-26-005093.md) | [378](/filings/0001477932-25-008343.md) | [(4.0) d](/filings/0001477932-26-002218.md) | [(0.8)](/filings/0001477932-26-003242.md) | [13.0](/filings/0001477932-26-005093.md) |
| Research and development | $k | not reported | not reported | [11.5](/filings/0001477932-25-003821.md) | [8.2](/filings/0001477932-25-006023.md) | [10.4](/filings/0001477932-25-008343.md) | [17.4 d](/filings/0001477932-26-002218.md) | [12.1](/filings/0001477932-26-003242.md) | [12.6](/filings/0001477932-26-005093.md) | [14.9](/filings/0001477932-25-008343.md) | [11.1 d](/filings/0001477932-26-002218.md) | [14.5](/filings/0001477932-26-003242.md) | [13.7](/filings/0001477932-26-005093.md) |
| Operating income | $k | [(2,529)](/filings/0001477932-24-007332.md) | [258 d](/filings/0001477932-25-002725.md) | [(79.0)](/filings/0001477932-25-003821.md) | [259](/filings/0001477932-25-006023.md) | [(1,338)](/filings/0001477932-25-008343.md) | [(416) d](/filings/0001477932-26-002218.md) | [(618)](/filings/0001477932-26-003242.md) | [(611)](/filings/0001477932-26-005093.md) | [(703)](/filings/0001477932-25-008343.md) | [(1,033) d](/filings/0001477932-26-002218.md) | [(540)](/filings/0001477932-26-003242.md) | [(282)](/filings/0001477932-26-005093.md) |
| Interest expense | $k | [4.3](/filings/0001477932-24-007332.md) | [4.2 d](/filings/0001477932-24-002151.md) | [4.7](/filings/0001477932-24-002941.md) | [4.5 d](/filings/0001477932-24-004792.md) | [6.2](/filings/0001477932-24-007332.md) | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Income tax | $k | [76.4](/filings/0001477932-24-007332.md) | [(97.9) d](/filings/0001477932-25-002725.md) | [(20.1)](/filings/0001477932-25-003821.md) | [55.6](/filings/0001477932-25-006023.md) | [1.6](/filings/0001477932-25-008343.md) | [(80.7) d](/filings/0001477932-26-002218.md) | [0.0](/filings/0001477932-26-003242.md) | [0.0](/filings/0001477932-26-005093.md) | [0.0](/filings/0001477932-25-008343.md) | [0.0 d](/filings/0001477932-26-002218.md) | [0.0](/filings/0001477932-26-003242.md) | [0.0](/filings/0001477932-26-005093.md) |
| Net income | $k | [(2,609)](/filings/0001477932-24-007332.md) | [308 d](/filings/0001477932-25-002725.md) | [(104)](/filings/0001477932-25-003821.md) | [199](/filings/0001477932-25-006023.md) | [(1,345)](/filings/0001477932-25-008343.md) | [(348) d](/filings/0001477932-26-002218.md) | [(623)](/filings/0001477932-26-005093.md) | [(616)](/filings/0001477932-26-005093.md) | [(709)](/filings/0001477932-25-008343.md) | [(1,036) d](/filings/0001477932-26-002218.md) | [(544)](/filings/0001477932-26-005093.md) | [(286)](/filings/0001477932-26-005093.md) |
| Diluted EPS | $ per share | not reported | not reported | [(0.01)](/filings/0001477932-25-003821.md) | [0.11](/filings/0001477932-25-006023.md) | [(0.75)](/filings/0001477932-25-008343.md) | not reported | [(0.35)](/filings/0001477932-26-003242.md) | [(0.34)](/filings/0001477932-26-005093.md) | [(0.40)](/filings/0001477932-25-008343.md) | not reported | [(0.23)](/filings/0001477932-26-003242.md) | [(0.12)](/filings/0001477932-26-005093.md) |

- Revenue: us-gaap:Revenues
- Cost of revenue: us-gaap:CostOfRevenue
- Gross profit: us-gaap:GrossProfit
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: us-gaap:InterestExpense
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [4.7](/filings/0001477932-24-001468.md) | [2.6](/filings/0001477932-24-002941.md) | [2.5](/filings/0001477932-24-002941.md) | not reported | not reported | [2.9](/filings/0001477932-26-002218.md) | not reported | not reported | not reported | [2.4](/filings/0001477932-26-005093.md) | not reported | [1.2](/filings/0001477932-26-005093.md) |
| Current assets | $m | [8.3](/filings/0001477932-24-001468.md) | [8.0](/filings/0001477932-25-002725.md) | [7.9](/filings/0001477932-24-002941.md) | [7.8](/filings/0001477932-24-004792.md) | [7.0](/filings/0001477932-24-007332.md) | [7.4](/filings/0001477932-26-002218.md) | [6.5](/filings/0001477932-25-003821.md) | [6.4](/filings/0001477932-25-006023.md) | [5.6](/filings/0001477932-25-008343.md) | [5.4](/filings/0001477932-26-005093.md) | [5.2](/filings/0001477932-26-003242.md) | [4.9](/filings/0001477932-26-005093.md) |
| Total assets | $m | [11.5](/filings/0001477932-24-001468.md) | [11.4](/filings/0001477932-25-002725.md) | [11.2](/filings/0001477932-24-002941.md) | [11.1](/filings/0001477932-24-004792.md) | [11.0](/filings/0001477932-24-007332.md) | [10.4](/filings/0001477932-26-002218.md) | [9.5](/filings/0001477932-25-003821.md) | [9.4](/filings/0001477932-25-006023.md) | [7.6](/filings/0001477932-25-008343.md) | [9.3](/filings/0001477932-26-005093.md) | [9.0](/filings/0001477932-26-003242.md) | [8.7](/filings/0001477932-26-005093.md) |
| Current liabilities | $m | [1.6](/filings/0001477932-24-001468.md) | [1.6](/filings/0001477932-25-002725.md) | [1.7](/filings/0001477932-24-002941.md) | [1.4](/filings/0001477932-24-004792.md) | [1.4](/filings/0001477932-24-007332.md) | [2.0](/filings/0001477932-26-002218.md) | [1.6](/filings/0001477932-25-003821.md) | [1.8](/filings/0001477932-25-006023.md) | [0.7](/filings/0001477932-25-008343.md) | [0.5](/filings/0001477932-26-005093.md) | [0.8](/filings/0001477932-26-003242.md) | [0.8](/filings/0001477932-26-005093.md) |
| Total liabilities | $m | [1.8](/filings/0001477932-24-001468.md) | [1.7](/filings/0001477932-25-002725.md) | [1.8](/filings/0001477932-24-002941.md) | [1.6](/filings/0001477932-24-004792.md) | [1.6](/filings/0001477932-24-007332.md) | [2.1](/filings/0001477932-26-002218.md) | [1.7](/filings/0001477932-25-003821.md) | [1.9](/filings/0001477932-25-006023.md) | [0.8](/filings/0001477932-25-008343.md) | [0.6](/filings/0001477932-26-005093.md) | [0.9](/filings/0001477932-26-003242.md) | [0.9](/filings/0001477932-26-005093.md) |
| Shareholders' equity | $m | [9.3](/filings/0001477932-24-007332.md) | [9.7](/filings/0001477932-26-002218.md) | [9.3](/filings/0001477932-25-008343.md) | [9.5](/filings/0001477932-25-008343.md) | [9.4](/filings/0001477932-25-008343.md) | [8.3](/filings/0001477932-26-005093.md) | [7.8](/filings/0001477932-26-005093.md) | [7.5](/filings/0001477932-26-005093.md) | [6.8](/filings/0001477932-25-008343.md) | [8.6](/filings/0001477932-26-005093.md) | [8.1](/filings/0001477932-26-005093.md) | [7.8](/filings/0001477932-26-005093.md) |

- Cash and equivalents: us-gaap:Cash, us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $k | [(899) d](/filings/0001477932-24-007332.md) | [(783) d](/filings/0001477932-25-002725.md) | [(37.2)](/filings/0001477932-25-003821.md) | [(672) d](/filings/0001477932-25-006023.md) | [(1,603) d](/filings/0001477932-25-008343.md) | [219 d](/filings/0001477932-26-002218.md) | [(824)](/filings/0001477932-26-003242.md) | [(738) d](/filings/0001477932-26-005093.md) | [(1,237) d](/filings/0001477932-25-008343.md) | [961 d](/filings/0001477932-26-002218.md) | [(148)](/filings/0001477932-26-003242.md) | [(422) d](/filings/0001477932-26-005093.md) |
| Capital expenditure | $k | [134 d](/filings/0001477932-24-007332.md) | [0.9 d](/filings/0001477932-25-002725.md) | [21.9](/filings/0001477932-25-003821.md) | [1.8 d](/filings/0001477932-25-006023.md) | [199 d](/filings/0001477932-25-008343.md) | [4.0 d](/filings/0001477932-26-002218.md) | [9.1](/filings/0001477932-26-003242.md) | [21.5 d](/filings/0001477932-26-005093.md) | [5.5 d](/filings/0001477932-25-008343.md) | [1.0 d](/filings/0001477932-26-002218.md) | [0.3](/filings/0001477932-26-003242.md) | [0.3 d](/filings/0001477932-26-005093.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment

## Shares

| Line item | Unit | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [17.7](/filings/0001477932-25-003821.md) | [1.8](/filings/0001477932-25-006023.md) | [1.8](/filings/0001477932-25-008343.md) | [1.8](/filings/0001477932-26-003242.md) | [1.8](/filings/0001477932-26-005093.md) | [1.8](/filings/0001477932-25-008343.md) | [2.4](/filings/0001477932-26-003242.md) | [2.4](/filings/0001477932-26-005093.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 2,933,442 at 2026-08-14, from the cover of the [10-Q filed 2026-08-14](/filings/0001477932-26-005093.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:47 ET. No prices; not investment advice.